3,4-diphenethoxybenzaldehyde

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3,4-diphenethoxybenzaldehyde
• 英文别名: 3,4-bis(2-phenylethoxy)benzaldehyde
• 化学式: C₂₃H₂₂O₃
• 分子量: 346.426
• InChiKey: YCIBMPLMAHWJSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,4-diphenethoxybenzaldehyde 在 palladium 10% on activated carbon 、 氢气 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 20.0 ℃ 、500.01 kPa 条件下， 反应 47.0h， 生成 ethyl 2-(3,4-diphenethoxybenzyl)hexanoate
  参考文献：
  名称：

  Discovery and Biological Evaluation of a Novel Class of Dual Microsomal Prostaglandin E₂ Synthase-1/5-lipoxygenase Inhibitors Based on 2-[(4,6-Diphenethoxypyrimidin-2-yl)thio]hexanoic Acid

  摘要：

  Various inflammatory diseases are associated with the excessive formation of leukotrienes (LTs) and prostaglandins (PGs). Herein, we present a novel class of dual inhibitors of 5-lipoxygenase (5-LO) and microsomal prostaglandin E-2 synthase-1 (mPGES-1), key enzymes in the formation of LTs and PGE(2), respectively. On the basis of the structure of 2-[(4,6-diphenethoxypyrimidin-2-yl-)thio]hexanoic acid (1), we performed a detailed SAR analysis, and mechanistic studies were carried out to elucidate the mode of 5-LO inhibition. Interestingly, the pyrimidine ring including the thioether of 1 could be replaced by a simple benzyl or a benzylidene moiety yielding a novel series of bioactive 2-benzylidene- and 2-benzylhexanoic acids exemplified by 2-(2,3-diphenethoxybenzylidene)hexanoic acid, 29 (IC50 5-LO = 0.8 mu M; mPGES-1 = 1.1 mu M). Importantly, none of the novel bioactive derivatives strongly inhibited cyclooxygenase activities. Together, we provide novel promising lead compounds for the treatment of inflammatory diseases valuable for further investigations in vivo.

  DOI：

  10.1021/jm200092b
• 作为产物：
  描述：

  3,4-二羟基苯甲醛 在 偶氮二甲酸二异丙酯 、 potassium carbonate 、 三苯基膦 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 32.0h， 生成 3,4-diphenethoxybenzaldehyde
  参考文献：
  名称：

  EP3828164

  摘要：

  公开号：

文献信息

• Studies on antidiabetic agents. III. 5-Arylthiazolidine-2,4-diones as potent aldose reductase inhibitors.
  作者：TAKASHI SOHDA、KATSUTOSHI MIZUNO、EIKO IMAMIYA、HIROYUKI TAWADA、KANJI MEGURO、YUTAKA KAWAMATSU、YUJIRO YAMAMOTO

  DOI：10.1248/cpb.30.3601

  日期：——

  Thiazolidine-2, 4-dione derivatives having one or two substituent (s) such as phenyl, heteryl and alkyl group (s) at the 5-position were synthesized and evaluated as aldose reductase inhibitors. Inhibition by the active compounds of the swelling of the lens in a rat-lens-culture assay was also measured. Among these compounds, a series of 5-(3, 4-dialkoxyphenyl) thiazolidine-2, 4-diones showed pronounced activities in both assays. Structure-activity relationships are discussed and a new approach to the synthesis of 5-arylthiazolidine-2, 4-diones is described.

  具有一个或两个取代基（如苯基、杂基和烷基）的噻唑烷-2,4-二酮衍生物在5位合成并评估为醛糖还原酶抑制剂。在鼠晶状体培养检测中，活性化合物的抑制作用也被测量。在这些化合物中，一系列5-(3,4-二烷氧基苯基)噻唑烷-2,4-二酮在两种检测中显示出显著的活性。结构-活性关系进行了讨论，并描述了一种合成5-芳基噻唑烷-2,4-二酮的新方法。
• NOVEL COMPOUND AND PHARMACETICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR METABOLIC SYNDROME COMPRISING THEREOF
  申请人：PROTECH CO., LTD.

  公开号：US20210024454A1

  公开（公告）日：2021-01-28

  The present invention provides a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof which can be effectively used for preventing or treating obesity or metabolic syndrome, and a pharmaceutical composition comprising the same. in Chemical Formula 1, R 1 and R 2 are the same as defined in the specification.

  本发明提供了一种化合物，其化学式如下所示：化学式1或其在药学上可接受的盐，可有效用于预防或治疗肥胖或代谢综合征，并且包括该化合物的药物组合物。在化学式1中，R1和R2与规范中定义的相同。
• NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR METABOLIC SYNDROME COMPRISING SAME
  申请人：Protech Co., Ltd.

  公开号：EP3778555A1

  公开（公告）日：2021-02-17

  The present invention provides a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof which can be effectively used for preventing or treating obesity or metabolic syndrome, and a pharmaceutical composition comprising the same. in Chemical Formula 1, R1 and R2 are the same as defined in the specification.

  本发明提供了一种由下化学式 1 所代表的化合物或其药学上可接受的盐，可有效用于预防或治疗肥胖症或代谢综合征，以及包含该化合物的药物组合物。 在化学式 1 中 R1 和 R2 与说明书中定义的相同。
• NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, ALLEVIATING, OR TREATING PROTEIN ABNORMALITY DISORDERS
  申请人：Protech Co., Ltd.

  公开号：EP3828162A1

  公开（公告）日：2021-06-02

  The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

  本发明涉及一种新型 p62 配体化合物、其立体异构体、水合物、溶质或原药，以及以其为活性成分的用于预防或治疗蛋白病的药物或食品组合物。根据本发明的 p62 配体化合物通过激活细胞自噬，从而选择性地消除体内蛋白质、细胞器和聚集物，可有效地用作药物组合物，用于预防、改善或治疗各种蛋白质病。
• NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME
  申请人：Protech Co., Ltd.

  公开号：EP3828163A1

  公开（公告）日：2021-06-02

  The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating misfolded protein diseases comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating selective autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

  本发明涉及一种新型 p62 配体化合物、其立体异构体、水合物、溶质或原药，以及以其为活性成分的用于预防或治疗折叠错误蛋白质疾病的药物或食品组合物。根据本发明的 p62 配体化合物通过激活细胞中的选择性自噬，从而选择性地消除体内蛋白质、细胞器和聚集体，可有效地用作预防、改善或治疗各种蛋白质疾病的药物组合物。